News Background

Oxford, UK – 02 July 2018. OGT, The Molecular Genetics Company, has announced that it is now directly selling CytoCell Fluorescence In Situ Hybridisation (FISH) products through several established affiliates of Sysmex Corporation in Europe following its acquisition last year. The move is a testament to the ongoing successful integration of the two companies and commitment to combine efforts to support and serve end users. CytoCell customers in Poland, Czechia, and Slovakia began benefitting from Sysmex’s established sales and support infrastructure on 1st May, with customers in France, Belgium, Switzerland, and Luxembourg joining them on 1st July, 2018.

As one of the top 10 IVD companies worldwide, Sysmex is well-respected and established in the field of haematology and urinalysis and has a growing focus on life sciences, pathology and personalised medicine. OGT’s CytoCell brand offers the widest range of high-quality, reliable, and cost-effective FISH probes on the market. CytoCell is well known for its comprehensive range, exceptional customer support, service, and expertise. Since the acquisition of OGT by Sysmex last year, the companies have been working hard to develop both commercial and product synergies across their portfolios with a strong focus on growth in molecular diagnostics. OGT is also collaborating with Sysmex to develop an automated FISH testing system, combining OGT’s FISH reagent expertise with Sysmex’s instrumentation technology.

Spencer Howell, Executive VP Sales at OGT, commented, “We’re delighted that our CytoCell customers can now access the benefits of the excellent Sysmex sales and support services in Europe. Sysmex is committed to growing our CytoCell portfolio with new products and by combining its expertise in instrumentation with ours in FISH probe design. Providing our products through the large, experienced, Sysmex sales network and excellent support infrastructure will enable us to grow the business in new areas—namely molecular diagnostics—to provide even more innovative products and solutions for our customers”

OGT anticipates it will also sell its CytoSure™ microarray and SureSeq™ next generation sequencing (NGS) product portfolio through Sysmex in the near future.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

Related content

  • Share

You might also be interested in

OGT celebrates opening of new Cambridge site Listing Image

OGT celebrates opening of new Cambridge site

06 Jun 2019

State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.

Read
FDA grants de novo designation for OGT’s AML/MDS FISH probes Listing Image

FDA grants de novo designation for OGT’s AML/MDS FISH probes

30 Jan 2019

Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter